CorpDigest
Gilead Sciences, Inc.
Leadership History
4 leaders · Full leadership timeline
Last reviewed: 2026-06-08 · By Swet Parvadiya
The financial mechanics of this diversified model are exceptionally complex, requiring the simultaneous management of a high-volume, high-margin small molecule manufacturing network for HIV therapies, and a highly customized, logistically complex autologous cell therapy supply chain for oncology. This margin structure is vastly superior to the 15-20% margins typical of generic manufacturers, but it requires massive upfront capital deployment in specialized manufacturing facilities and clinical development programs. The revenue streams are heavily concentrated in a few massive blockbuster franchises. The antibody-drug conjugate (ADC) model used by Trodelvy involves attaching a highly potent cytotoxic payload, specifically SN-38, to a monoclonal antibody that targets the Trop-2 receptor expressed on the surface of cancer cells. The CAR-T cell therapy model used by Yescarta represents a fundamentally different economic model, requiring the extraction of a patient's own T cells, their genetic modification using a lentiviral vector to express a chimeric antigen receptor, and their reinfusion into the patient after a complex manufacturing process that takes approximately three weeks. The commercial infrastructure required to support this model is highly specialized. Gilead employs a sales force of thousands of highly trained scientific liaisons who engage directly with infectious disease specialists, oncologists, and hematologists, providing complex clinical data rather than simple product pitches. In the oncology space, the competitive dynamics are far more complex. Companies like Regeneron in oncology and Vertex in rare diseases operate with lower overhead and higher R&D efficiency, allowing them to bring novel modalities to market faster than a diversified giant like Gilead. This high gross margin is characteristic of the innovative biopharmaceutical industry and reflects the relatively low marginal cost of manufacturing small molecule drugs and biologics once the initial capital-intensive manufacturing facilities have been built and the regulatory approvals have been obtained. The discontinuation of magrolimab in 2023 following Phase III trial failures in myelodysplastic syndromes resulted in a significant write-down and highlighted the unforgiving nature of late-stage clinical development.
Chief Executive Officer
Milligan assumed the role of CEO in January 2024, bringing over 20 years of experience at Gilead. He previously served as Executive Vice President of Corporate Operations, where he oversaw the commercial launch of Biktarvy and the integration of the Kite Pharma and Immunomedics acquisitions.
Executive Vice President, Chief Financial Officer
Dickinson manages the financial aspects of the company's diversified portfolio, including the capital allocation strategy for the massive R&D and manufacturing investments. He played a key role in maintaining the company's strong credit rating and investor confidence during the transition post-Veklury.
President, Global Commercial Organization
Mercier is responsible for driving the company's global commercial strategy, including the launch of Trodelvy and Yescarta and the navigation of the complex PBM rebate landscape in the US. She has led the expansion of the sales force and the implementation of data-driven commercial execution strategies.
Former Chief Executive Officer
O'Day served as CEO for a brief period in 2023, overseeing the initial stages of the company's transition to a diversified biopharmaceutical enterprise before stepping down to pursue other opportunities.
The competitive narrative in HIV prevention is equally dynamic, with the rapid emergence of long-acting injectables and oral NRTTIs threatening to displace daily oral PrEP as the standard of care. In the CAR-T cell therapy space, Yescarta is locked in a fierce battle with Bristol Myers Squibb's Abecma and Carvykti, while simultaneously facing the long-term threat of allogeneic 'off-the-shelf' CAR-T therapies developed by Allogene Therapeutics and CRISPR Therapeutics, which could potentially eliminate the complex, expensive autologous manufacturing process that currently defines the Gilead oncology model. The company's response to these challenges has been to pivot aggressively toward next-generation modalities, including bispecific antibodies, targeted protein degraders, and novel cell therapies, but this pivot requires massive capital expenditure and carries high binary clinical risk. These facilities are equipped with proprietary closed-system processing technologies and specialized clean rooms that minimize contamination risks and ensure the consistent, high-yield production of the final drug product.
However, this optimistic outlook is contingent on the successful navigation of several key risks, including the potential for clinical trial failures, increased regulatory pricing pressure in the US and Europe, and the continued threat of generic competition for legacy HIV assets.
John C. Martin served as Gilead's CEO from 1996 to 2016, a two-decade run that transformed the company from a struggling antiviral startup into a virology giant. His defining decision was the roughly $11 billion 2011 Pharmasset acquisition that unlocked the hepatitis C franchise.
John Milligan became Gilead's CEO in 2016 after serving as president and chief operating officer, and he led the company until early 2019. His tenure included the $11.9 billion 2017 Kite Pharma acquisition that launched Gilead into cell therapy.
Daniel O'Day became Gilead's chief executive in March 2019, arriving from Roche where he had headed the pharmaceuticals division. He was recruited to diversify Gilead beyond its concentrated HIV franchise and reinvigorate its oncology ambitions.
Since 2019 O'Day has directed the roughly $21 billion 2020 Immunomedics acquisition and prioritized the development of the long-acting HIV agent lenacapavir. His approach favors late-stage, de-risked assets in areas where Gilead already has commercial scale, backed by a $4.5 billion annual R&D budget.